Abstract
Aim: Final overall survival (OS) and time on treatment analysis of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and osimertinib. Patients & methods: Patients (n = 203) had T790M-positive disease following first-line afatinib and started osimertinib treatment ≥10 months before data entry. Primary outcome was time on treatment; OS analysis was exploratory. Results: Median time on treatment with afatinib and osimertinib was 27.7 months (90% CI: 26.7-29.9). Median OS was 37.6 months (90% CI: 35.5-41.3); median OS was 41.6 and 44.8 months in Del19-positive patients and Asian patients, respectively. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib was associated with encouraging outcomes in patients with EGFR mutation-positive NSCLC, especially in Del19-positive patients and Asian patients. Clinical Trial Registration: NCT03370770 (ClinicalTrials.gov.
Original language | English (US) |
---|---|
Pages (from-to) | 2799-2808 |
Number of pages | 10 |
Journal | Future Oncology |
Volume | 16 |
Issue number | 34 |
DOIs | |
State | Published - Dec 2020 |
Keywords
- EGFR
- NSCLC
- afatinib
- osimertinib
ASJC Scopus subject areas
- Oncology
- Cancer Research